DEVELOPMENT, CHARACTERIZATION, AND EVALUATION OF SELEGILINE BIONANOSUSPENSIONS USING BUCHANANIA LANZAN AS BIOSTABILIZER
Objective: Development and evaluation of selegiline-loaded bio-nanosuspensions using biopolymer which was isolated from seeds of Buchanania lanzan (Chironji), used as biostabilizer and compared with standard polymer.
Methods: The selegiline-loaded bio-nanosuspensions were prepared using novel biopolymer and standard stabilizer (hydroxypropyl methylcellulose) by sonication solvent evaporation method with different ratios (1%, 2%, 3%, 4%, and 5%) and evaluated for particle size, polydispersity index, zeta potential, pH stability studies, percentage entrapment efficacy, in vitro drug release, and stability studies.
Results: The prepared selegiline bio-nanosuspensions were subjected to the best formulation based on comparison of above-mentioned evaluation parameters, so Fb2 (2%) formulation was found to be the best formulation showing an R2=0.9842, T50% of 32 h and T80% of 70 h, respectively. According to the release kinetics, the best fit model was found to be Peppas-Korsmeyer with Fickian diffusion (Higuchi matrix) as the mechanism of drug release, and Fs5 (5%) formulation was found to be the best formulation showing an R2=0.9564, T50% of 25 h and T80% of 60 h, respectively. According to the release kinetics, the best fit model was found to be Peppas-Korsmeyer with Fickian diffusion (Higuchi matrix) as the mechanism of drug release. The biopolymer provided excellent stability for the formulation and resulting particle size for the best formulation was found to be 360 nm. The best formulation was found to be polydispersity index of 0.43 with zeta potential of −5.12 mV.
Conclusion: The prepared bio-nanosuspensions using biopolymer were found to be safe and compatible with the novel drug delivery for the treatment of depression in comparison of standard polymer.
2. Banyopadhyay A, Banerjee S. Buchanania lanzan spreng: A vegetable store house of phytomedicines. Asian J Pharm Clin Res 2015;5:18-22.
3. Preskon SH. Why the transdermal delivery of selegiline (6mg/24h) obviates the need for a dietary restriction on tyramine. J Psychiatr Pract 2006;12:168-72.
4. Nandagopal JJ, DelBello MP. Selegiline transdermal system: A novel treatment option for major depressive disorder. Expert Opin Pharm 2009;10:1665-73.
5. McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM, et al. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharm Bull 1989;25:63-7.
6. Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50.
7. Prasad A, Glover V, Goodwin BL, Sandler M, Signy M, Smith SE, et al. Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment. Psychopharmacology (Berl) 1988;95:540-3.
8. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994;51:607-15.
9. Kesisoglou F, Panmai S, Wu Y. Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631-44.
10. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011;16:354-60.
11. Shegokar R, Müller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010;399:129-39.
12. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-96.
13. Verma S, Huey BD, Burgess DJ. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir 2009;25:12481-7.
14. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3-16.
15. Wang Y, Zhang D, Liu Z, Liu G, Duan C, Jia L, et al. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 2010;21:155104.
16. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897;19:930-4.
17. Muller RH, Peters K, Becker R, Kruss B. Nanosuspensions - A Novel for-Mulation for The i.v. Administration of Poorly Soluble Drugs. In 7th International Conference on Pharmaceutical Technology (APV: APGI) Budapest; 1995. p. 491-2.
18. Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical Nanosuspensions for Medicament Administration as System of Increased Saturation Solubility and Rate of Solution. US Patent, No. 5858410; 1998.
19. Han M, Yu X, Guo Y, Wang Y, Kuang H, Wang X, et al. Honokiol nanosuspensions: Preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system. Colloids Surf B Biointerfaces 2014;116:114-20.
20. Pandey AV, Vaidya PD, Arora A, Dhoka MV. Investigation of influence of shape on drug loading and entrapment efficiency of nanoparticles. J Pharm Res 2017;7:850-5.
21. Dattatraya SM, Loknete JD. Formulation and in vitro evaluation of fast dissolving tablet of verapamil hydrochloride. Int J Pharm Pharm Sci 2018;10:93-9.
22. Madhav NV, Yadav AP. A novel translabial platform utilizing bioexcipients from Litchi Chinesis for the delivery of rosiglitazone maleate. Acta Pharm Sin B 2013;6;408-15.
23. Kotecha RK, Bhadra S, Rjesh KS. Formulation and process development of azithromycin ophthalmic nanosuspension. Int J Pharm Pharm Sci 2013;4:490-7.
24. Madhav NV, Raina D. Formulattion and performaace evaluation of escitalopram loaded bionanosuspension using a novel bio-retardent from Piper nigerum. Int J Life Sci Rev 2017;5:60-6.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.